A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2006
12/05/2006	CA2262840C Improved method for systemic administration of 2,4-dienoic acid-type insecticides to terrestrial mammals
12/05/2006	CA2245728C Isoquinoline derivatives and drugs
12/05/2006	CA2215067C Use of betulinic acid and its derivatives for inhibiting malignant melanoma growth and a method of monitoring this
12/05/2006	CA2214327C Aqueous spectinomycin borate solutions
12/05/2006	CA2203079C 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]indoles as estrogenic agents
12/05/2006	CA2203078C 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]indoles as estrogenic agents
12/05/2006	CA2193531C Method for preparing 4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,7.beta.,10.beta.-trihydroxy-9-oxo-tax-11-en-13.alpha.-yl(2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate trihydrate
12/05/2006	CA2189652C Novel hydroximic acid derivatives, pharmaceutical compositions containing them and process for preparing same
12/05/2006	CA2185524C Ocular tension depressant
12/05/2006	CA2176604C Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin
12/05/2006	CA2159058C Inhibition of helicobacter
12/05/2006	CA2150382C Process for the preparation of 9-amino camptothecin
12/05/2006	CA2146429C 25-carboxylic acid derivatives in the vitamin d series, method of producing them, intermediate products for this method, pharmaceutical preparations containing these derivatives and their use in the manufacture of medicines
12/05/2006	CA2142530C Topical compositions containing benzoyl peroxide and clindamycin and method of use thereof
12/05/2006	CA2130787C Ursodeoxycholic acid-containing medicament in a liquid administration form
12/05/2006	CA2108265C Methods and compositions for isolating taxanes
12/04/2006	CA2558746A1 Use of paliperidone for the treatment of substance abuse
12/03/2006	CA2547744A1 Linear dicationic terphenyls and their aza analogues as antiparasitic agents
12/02/2006	CA2510119A1 Modified-release composition of at least one form of venlafaxine
12/02/2006	CA2509124A1 Modified-release composition of at least one form of venlafaxine
11/2006
11/30/2006	WO2006128184A2 Pyrimidine or triazine fused bicyclic metalloprotease inhibitors
11/30/2006	WO2006128173A2 Selective apoptotic induction in cancer cells including activation of procaspase-3
11/30/2006	WO2006128172A2 Method for treating b cell regulated autoimmune disorders
11/30/2006	WO2006128169A2 Inhibition of monocyte survival, differentiation, or proliferation
11/30/2006	WO2006128150A2 Crystalline solid forms of tigecycline and methods of preparing same
11/30/2006	WO2006128142A2 Inhibitors of cytosolic phospholipase a2
11/30/2006	WO2006128129A2 Method for treating cancer
11/30/2006	WO2006128121A2 Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
11/30/2006	WO2006128088A1 Novel propofol composition comprising a pharmaceutically acceptable salt of formaldehyde sulfoxylate
11/30/2006	WO2006128070A2 Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a gabab receptor agonist
11/30/2006	WO2006128048A2 Methods and compositions for reducing blood homocysteine levels
11/30/2006	WO2006128045A2 Use of polyamines with antibiotics
11/30/2006	WO2006128035A2 Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
11/30/2006	WO2006128022A2 Solid compositions and methods for treating middle-of-the night insomnia
11/30/2006	WO2006128009A2 Supplement composition and method of use for enhancement of dna repair process
11/30/2006	WO2006127996A2 Compositions and methods for optimizing exercise recovery
11/30/2006	WO2006127977A1 Fatty acid carbohydrate hybrid molecules as therapeutic agents and methods thereof
11/30/2006	WO2006127961A1 Enhanced indolinone based protein kinase inhibitors
11/30/2006	WO2006127945A1 Compositions and methods of treating retinal disease
11/30/2006	WO2006127941A2 Amorphous cinacalcet hydrochloride and preparation thereof
11/30/2006	WO2006127938A1 Methods and compositions using 4[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperridin-3yl) isoindole-1,3-dione for the treatment of prevention of cutaneous lupus
11/30/2006	WO2006127932A2 Purification of cinacalcet
11/30/2006	WO2006127930A2 Nk-b inhibitors for the treatment of muscular dystrophy
11/30/2006	WO2006127926A2 Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
11/30/2006	WO2006127909A2 Polymorphic forms of (s)-1-cyanobutan-2-yl (s)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) phenyl) ethylcarbamate
11/30/2006	WO2006127907A2 Localized delivery of cardiac inotropic agents
11/30/2006	WO2006127906A1 Heterobifunctional compounds for selectin inhibition
11/30/2006	WO2006127899A2 (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use
11/30/2006	WO2006127898A2 (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
11/30/2006	WO2006127893A2 Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
11/30/2006	WO2006127810A2 Bacterial cellulose-containing formulations and method of producing effective bacterial cellulose-containing formulations
11/30/2006	WO2006127779A2 Supplement composition and method of use for enhancement of insulin sensititivy
11/30/2006	WO2006127759A2 Antioxidant supplement composition and method of use
11/30/2006	WO2006127748A1 Use of huperzine for disorders
11/30/2006	WO2006127650A1 Methods for diagnosing epigenetic, transgenerational effects of environmental toxicants on mammalian germ-lines and treating associated diseases
11/30/2006	WO2006127649A2 Co-biocidal formulation for polymeric materials
11/30/2006	WO2006127627A2 Compostions containing pufa and/or uridine and methods of use thereof
11/30/2006	WO2006127620A2 Compositions containing pufa and methods of use thereof
11/30/2006	WO2006127595A1 5-aminopyrazole carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof
11/30/2006	WO2006127591A2 Organic nitric oxide enhancing salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
11/30/2006	WO2006127587A1 Pyrrolopyridines useful as inhibitors of protein kinase
11/30/2006	WO2006127584A1 Imidazolone phenylalanine derivatives as vla-4 antagonists
11/30/2006	WO2006127574A2 Method for the treatment of noise phobia in companion animals
11/30/2006	WO2006127530A2 Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
11/30/2006	WO2006127525A2 Proteasome inhibitors and uses thereof
11/30/2006	WO2006127482A1 Methylene blue therapy of viral disease
11/30/2006	WO2006127458A2 Novel chemical compounds
11/30/2006	WO2006127418A1 Scopolamine for the treatment of depression and anxiety
11/30/2006	WO2006127399A2 Versatile high load concentrate compositions comprising metaflumizone for control of ecto-parasites
11/30/2006	WO2006127396A1 Par2-modulating compounds and their use
11/30/2006	WO2006127379A2 Par2-modulating compounds and their use
11/30/2006	WO2006127368A2 Methods for synthesizing imidazotriazinones
11/30/2006	WO2006127364A1 Apoptosis promoters
11/30/2006	WO2006127331A2 Conversion process for 2,3-benzodiazepine enantiomers
11/30/2006	WO2006127329A1 Quinoline derivatives useful as modulators of ion channels
11/30/2006	WO2006127289A1 Treatment of hcv with subtherapeutic doses of ribavirin
11/30/2006	WO2006127287A2 Pyrrolopyridine-based inhibitors of dipeptidyl peptidase iv and methods
11/30/2006	WO2006127284A2 Method of purifying apo-2 ligand/trail using crystallisation in the cold
11/30/2006	WO2006127252A1 Motilide compounds
11/30/2006	WO2006127217A2 Cyclopropanecarboxylate esters of acyclovir
11/30/2006	WO2006127207A1 Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
11/30/2006	WO2006127133A2 Compounds for the treatment of metabolic disorders
11/30/2006	WO2006127096A2 Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures
11/30/2006	WO2006127057A1 Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction
11/30/2006	WO2006127044A2 Pharmaceutical formulations useful for inhibiting acid secretion
11/30/2006	WO2006126972A1 Method of delivering nucleic acid molecules into embryonic stem cells using baculoviral vectors
11/30/2006	WO2006126948A1 Piperidines for the treatment of chemokine mediated diseases
11/30/2006	WO2006126947A1 Piperidines for the treatment of chemokine mediated diseases
11/30/2006	WO2006126939A1 Novel 8-sulfonylamino-3 aminosubstituted chroman or tetrahydronaphtalene derivatives modulating the 5ht6 receptor
11/30/2006	WO2006126938A1 Novel 8-sulfonyl-3 aminosubstituted chroman or tetrahydronaphtalene derivatives modulating the 5ht6 receptor
11/30/2006	WO2006126718A1 Pyrazolopyrimidine derivative
11/30/2006	WO2006126714A1 Activator for peroxisome proliferator-activated receptor
11/30/2006	WO2006126712A1 Smooth muscle contraction inhibitor
11/30/2006	WO2006126695A1 Pyrazole compound and therapeutic agent for diabetes comprising the same
11/30/2006	WO2006126681A1 Pharmaceutical composition
11/30/2006	WO2006126676A1 Cyclic amine derivative having substituted alkyl group
11/30/2006	WO2006126673A1 Combined drug for treating diabetes
11/30/2006	WO2006126663A1 Pharmaceutical preparation for recovery from fatigue
11/30/2006	WO2006126654A1 Novel compound colletoic acid
11/30/2006	WO2006126637A1 6,7-unsaturated-7-carbamoyl substituted morphinan derivative

1 ... 3983 3984 3985 3986 3987 3988 3989 3990 3991 3992 3993 3994 3995 3996 3997 3998 3999 4000 4001 4002 4003 ... 7860